標(biāo)題: Titlebook: Congenital Bleeding Disorders; Diagnosis and Manage Akbar Dorgalaleh Book 20181st edition Springer International Publishing AG, part of Spr [打印本頁(yè)] 作者: 召喚 時(shí)間: 2025-3-21 20:00
書目名稱Congenital Bleeding Disorders影響因子(影響力)
作者: Visual-Acuity 時(shí)間: 2025-3-21 20:28
Mojúbàolú Olúfúnké Okome,Olufemi Vaughantly in inherited platelet function disorders (IPFD), to severe life-threatening disorders, notably in factor (F) XIII deficiency. Most of these disorders including rare bleeding disorders (RBD) and IPFD are autosomal recessive disorders, while patients with hemophilia A and B had X-linked recessive 作者: cumulative 時(shí)間: 2025-3-22 01:07
Research Design and Methodology, is classified into three main types: type 1 and type 3 as quantitative deficiency and type 2 as qualitative defects. The bleeding tendency is highly variable in VWD, ranging from an asymptomatic condition, mainly in type 1 VWD, to severe life-threatening hemorrhage, most notably in type 3 VWD. Diag作者: fixed-joint 時(shí)間: 2025-3-22 07:13
Transnational Alliances in Higher Educationmale births, and is caused by a defect or deficiency in coagulation factor VIII (FVIII). Hemophilia A is due to different mutations in . gene; among them, intron 22 inversion, which leads to severe hemophilia A, is the most common. Patients with hemophilia A present different complications; among th作者: 后天習(xí)得 時(shí)間: 2025-3-22 10:08
https://doi.org/10.1057/9781137388803mmon than hemophilia A. Patients with hemophilia B suffer from recurrent joint bleeds, ecchymosis, epistaxis, and post-dental extraction bleeding. Nevertheless women who are carriers of this abnormality are asymptomatic. Timely diagnosis of disorder is made based on family history, clinical manifest作者: BAIT 時(shí)間: 2025-3-22 16:39 作者: BAIT 時(shí)間: 2025-3-22 19:38 作者: Conjuction 時(shí)間: 2025-3-22 22:17
https://doi.org/10.1057/9781137388803factor in the prothrombinase complex, which accelerates the conversion of prothrombin to thrombin. In addition, this coagulation factor has anticoagulant activity, which acts as a cofactor for activated protein C (APC) for downregulation of FVIII. Congenital FV deficiency, also termed parahemophilia作者: 抗生素 時(shí)間: 2025-3-23 03:11
Scarlett Yee-man Ng,Zhifeng Chen deficiency (MCFD) commonly represents as part of acquired conditions. The most well-known acquired causes are liver disease and disseminated intravascular coagulation (DIC) in which impaired synthesis or excessive consumption of coagulation factors occurs, respectively. Dilution states such as mass作者: 運(yùn)動(dòng)性 時(shí)間: 2025-3-23 07:43
Thinking Gender in Transnational Timess?have mild bleeding tendency, a considerable number of them present life-threatening bleedings such as central nervous system (CNS) and gastrointestinal (GI) bleedings. Although the diagnosis of congenital FVII deficiency is straightforward with isolated prolonged prothrombin time (PT) and decrease作者: 弄臟 時(shí)間: 2025-3-23 10:04
Transnational Anti-Gender Politicsed in autosomal recessive manner. Acquired form of FX deficiency is also rare and usually occurs in relation with AL amyloidosis. The most frequent bleeding diathesis in FX deficiency is mucosal bleedings such as epistaxis, gum bleeding, easy bruising, and menorrhagia. Spontaneous major bleedings su作者: Prostatism 時(shí)間: 2025-3-23 17:22 作者: Indolent 時(shí)間: 2025-3-23 20:36 作者: Outshine 時(shí)間: 2025-3-23 23:57 作者: 魅力 時(shí)間: 2025-3-24 02:23 作者: gentle 時(shí)間: 2025-3-24 10:02 作者: Figate 時(shí)間: 2025-3-24 13:02 作者: CHARM 時(shí)間: 2025-3-24 17:42 作者: 使堅(jiān)硬 時(shí)間: 2025-3-24 19:07 作者: novelty 時(shí)間: 2025-3-24 23:14
Internet Governance Forum: What Went Right?ore blood flow. The fibrinolysis system is one of the most important requirements for clot removal. Procoagulant and anticoagulant elements interacted complicatedly to ensure an effective response to vascular injury that is limited to the injured site.作者: 是限制 時(shí)間: 2025-3-25 03:33 作者: 首創(chuàng)精神 時(shí)間: 2025-3-25 08:28 作者: 有害 時(shí)間: 2025-3-25 11:52
https://doi.org/10.1057/9781137388803o confirm the diagnosis. A wide spectrum of mutations has been discovered in ., ., and . encoding the three chains of fibrinogen molecule. Two hotspot mutations are prevalent in afibrinogenemia and dysfibrinogenemia. Management of patients with congenital fibrinogen disorders is challenging and shou作者: GRACE 時(shí)間: 2025-3-25 19:02
https://doi.org/10.1057/9781137388803on laboratory tests should be used for diagnose of FII deficiency. FII deficiency is suspected through prolonged prothrombin time (PT) and activated thromboplastin time (aPTT) which was confirmed by a specific FII assay. As no specific prothrombin concentrate is available, prothrombin complex concen作者: 重力 時(shí)間: 2025-3-25 23:57
https://doi.org/10.1057/9781137388803n time (PT) and activate thromboplastin time (aPTT). The diagnosis is confirmed by specific diagnostic tests including FV antigen and activity assays. The only available therapeutic choice for patients with FV deficiency is fresh frozen plasma (FFP): the recommended dose is dependent on the location作者: fulmination 時(shí)間: 2025-3-26 02:59 作者: 強(qiáng)化 時(shí)間: 2025-3-26 08:13 作者: GRAVE 時(shí)間: 2025-3-26 11:26 作者: 心神不寧 時(shí)間: 2025-3-26 14:07
Manning Marable,Vanessa Agard-Joneswhereas for those with more severe hemorrhage, systemic hemostatic agents including platelet concentrates and recombinant?human activated?factor VII (rFVIIa) are used. Currently, platelet transfusion is the standard treatment, but repeated transfusion can result in allo-immunization and refractorine作者: Campaign 時(shí)間: 2025-3-26 20:50
https://doi.org/10.1057/9780230615397more specific laboratory studies such as aggregometry assays, flow cytometry, and molecular analysis can help to precise and timely diagnosis of disorder. BSS treatment includes supportive cares as well as specific treatment of bleeding episodes.作者: chronology 時(shí)間: 2025-3-26 22:19
An Overview of Hemostasisore blood flow. The fibrinolysis system is one of the most important requirements for clot removal. Procoagulant and anticoagulant elements interacted complicatedly to ensure an effective response to vascular injury that is limited to the injured site.作者: 真 時(shí)間: 2025-3-27 01:38 作者: 松馳 時(shí)間: 2025-3-27 06:33
von Willebrand Diseasere available in VWD including VWF/FVIII concentrates, recombinant VWF, desmopressin, and, in some locations, fresh frozen plasma (FFP). With timely diagnosis and appropriate management of the VWD, the burden of the disorder can be alleviated or even eliminated.作者: 細(xì)胞 時(shí)間: 2025-3-27 10:32 作者: 調(diào)味品 時(shí)間: 2025-3-27 17:29
Congenital Factor II Deficiencyon laboratory tests should be used for diagnose of FII deficiency. FII deficiency is suspected through prolonged prothrombin time (PT) and activated thromboplastin time (aPTT) which was confirmed by a specific FII assay. As no specific prothrombin concentrate is available, prothrombin complex concen作者: 辯論 時(shí)間: 2025-3-27 18:42 作者: incubus 時(shí)間: 2025-3-27 23:24
Multiple Coagulation Factor Deficiencyused by defect of a single gene that is implicated in the process or production/activation of multiple factors. The best examples include combined FV and FVIII deficiency (F5F8D) and vitamin K-dependent coagulation factors (VKDCF) deficiency, which have been thoroughly characterized. Isolated combin作者: 樂(lè)章 時(shí)間: 2025-3-28 05:43
Congenital Factor X Deficiency plasma. Then diagnosis should be confirmed by specific tests including antigenic (FX:Ag) and functional (FX:C) assays. Treatment of FX deficiency is based on replacement therapy by fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC). A single-factor FX concentrate produced from huma作者: beta-carotene 時(shí)間: 2025-3-28 08:59
Congenital Factor XIII Deficiencymmended as the first-line screening test, but a significant number of countries only used clot solubility test. For the treatment of congenital FXIII deficiency, different products are available, but FXIII concentrate is the treatment of choice. For primary prophylaxis, 10–40?IU/kg FXIII concentrate作者: 不能妥協(xié) 時(shí)間: 2025-3-28 11:40
Glanzmann Thrombastheniawhereas for those with more severe hemorrhage, systemic hemostatic agents including platelet concentrates and recombinant?human activated?factor VII (rFVIIa) are used. Currently, platelet transfusion is the standard treatment, but repeated transfusion can result in allo-immunization and refractorine作者: 小木槌 時(shí)間: 2025-3-28 17:02
Bernard-Soulier Syndromemore specific laboratory studies such as aggregometry assays, flow cytometry, and molecular analysis can help to precise and timely diagnosis of disorder. BSS treatment includes supportive cares as well as specific treatment of bleeding episodes.作者: neutral-posture 時(shí)間: 2025-3-28 19:17 作者: Sad570 時(shí)間: 2025-3-29 01:34 作者: Mucosa 時(shí)間: 2025-3-29 04:24
Hemophilia Bcurring in ~1% of patients remains as a challenge of replacement therapy that can cause infused FIX concentrate to be less efficient. Gene therapy is the only definitive curative option, but some time will pass before it becomes available as a routine treatment choice.作者: 泥土謙卑 時(shí)間: 2025-3-29 07:42
Book 20181st editionces for disease-related morbidity and mortality. The authors are acknowledged specialists in the field from across the world who have particular expertise in the disorder that they discuss. The book will be of value to hematologists, oncologists, pediatricians, laboratory specialists and technicians, general physicians, and trainees.?.作者: Estimable 時(shí)間: 2025-3-29 11:28
enges that they pose.Provides up-to-date guidance on use of This book describes in detail the clinical presentation, diagnosis, and management of a wide range of congenital bleeding disorders. It will assist readers in overcoming the significant challenges involved in clinical and laboratory diagnos作者: BUOY 時(shí)間: 2025-3-29 18:31
Daniela Meneses Sala,Corina Rueda-Borrerothe more frequent cross-reactive material negative (CRM?) and the rare cross-reactive material positive (CRM+). Different therapeutic choices are available including fresh frozen plasma (FFP) and FXI concentrates that can provoke inhibitor formation, while recombinant FVII can be used for such patients.作者: 含糊 時(shí)間: 2025-3-29 21:38
Book 20181st editionaders in overcoming the significant challenges involved in clinical and laboratory diagnosis and in providing effective clinical care that makes optimal use of new products, including recombinant factor. .concentrate. The coverage ranges from hemophilia A and B and von Willebrand disease to rare ble作者: 兩棲動(dòng)物 時(shí)間: 2025-3-30 01:06 作者: 和藹 時(shí)間: 2025-3-30 04:18 作者: 混雜人 時(shí)間: 2025-3-30 09:03
